Assessing the impact of season and schedule of vaccination on the immunogenicity of childhood vaccines

Assessing the impact of season and schedule of vaccination on the immunogenicity of childhood vaccines

Routine vaccination against a variety of childhood diseases has been instrumental in reducing infant and child mortality. Differences in vaccine schedules, including when an infant is first vaccinated against a disease, how many doses are given, and the length of time between vaccine doses, may impact how effective different vaccines are at generating immune responses. For example, past work has shown that infants who are older when first vaccinated have higher antibody levels, and some work has suggested that increasing the number of doses and the length of time between doses can also improve effectiveness. However, relatively few studies have explored these differences, and many other factors that may influence immune responses have received even less attention. This lack of evidence makes the development of evidence-based vaccine schedules a challenge, which in turn may explain why different countries often use substantially different vaccine schedules.   This project will explore the impact of various aspects of vaccine schedules on both the initial response to vaccination, as well as antibody levels over time, for several childhood infections. In particular, we will explore how the season during which a child is first vaccinated impacts response. Biological patterns that repeat at regular intervals, referred to as “biological rhythms,” are a universal aspect of human and animal biology. Some of the most frequently discussed examples of these rhythms include the sleep-wake cycle, or patterns in hormone secretion throughout the menstrual cycle. Past research has confirmed that biological rhythms are displayed by the human immune system, which undergoes regular changes in activity on both daily and yearly timescales. It is not difficult to imagine that these cycles may results in substantial differences in the strength of the immune response to vaccination, depending on the time of year in which a vaccine is received. Indeed, the idea that the immune system's ability to respond to infection and vaccination may vary noticeably by season has existed for decades. Despite this, very little research has been done on this topic, and studies designed to clarify how vaccine response may vary at different times of the year are needed.   We will explore the role of seasonality and of different vaccine schedules by combining data from clinical trials of several routine childhood vaccines. Specifically, we will aim to test the hypothesis that immune responses will vary seasonally, and that longer periods of time between vaccine doses will be associated with both stronger responses and longer duration of protection. Our approach, in which data from many trials are combined, improves our ability to identify meaningful results by increasing the number of children included in our sample, and by including children from different regions of the world.   Our results will have implications for the development of more optimized vaccine schedules, which may in turn lead to improved vaccine effectiveness. Our work will also improve the scientific community's general understanding of how immune system function varies by season.

[{ "PostingID": 134, "Title": "GSK-109507", "Description": "Booster Vaccination With Pneumococcal Vaccine GSK1024850A, a DTPa-Combined and MenC or Hib-MenC Vaccines" },{ "PostingID": 135, "Title": "GSK-110478", "Description": "Immunogenicity and reactogenicity study of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine administered as a booster dose to 18-23 months old children" },{ "PostingID": 136, "Title": "GSK-112157", "Description": "Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 3 and 4 months of age" },{ "PostingID": 137, "Title": "GSK-113978", "Description": "Immunogenicity and safety study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine administered as a booster dose in 12-18 months old healthy children" },{ "PostingID": 141, "Title": "GSK-104977", "Description": "Non-inferiority of one formulation of GSK Biologicals' DTPw-HBV/Hib to 2 formulations of GSK Biologicals' DTPw-HBV/Hib with respect to the immune response to the PRP antigen, when administered to healthy infants at 6, 10, 14 weeks of age" },{ "PostingID": 142, "Title": "GSK-113264", "Description": "Immunogenicity and reactogenicity of a booster dose of GlaxoSmithKline Biologicals’ GSK2036874A vaccine in healthy toddlers" },{ "PostingID": 143, "Title": "GSK-110058", "Description": "Immunogenicity of GlaxoSmithKline Biologicals' MMRV vaccine (208136) vs. ProQuad®, when coadministered with hepatitis A and pneumococcal conjugate vaccines to children 12-14 months of age." },{ "PostingID": 144, "Title": "GSK-110876", "Description": "Immunogenicity & safety study of GSK Biologicals’ combined measles-mumps-rubella-varicella vaccine 208136" },{ "PostingID": 145, "Title": "GSK-109995", "Description": "A phase IIIb, open, randomised, multicentre, primary study in healthy children, to establish the non-inferiority of GlaxoSmithKline (GSK) Biologicals’ MeMuRu-OKA vaccine (administered at 9 and 15 months of age) versus Priorix™ (9 months of age) and Priorix™ co-administered with Varilrix™ at 15 months of age (comparator) and also to evaluate the non-inferiority of Priorix™ (9 months of age) and MeMuRu-OKA vaccine (15 months of age) versus the comparator, all administered subcutaneously as two-dose primary vaccination course" },{ "PostingID": 153, "Title": "GSK-104567", "Description": "Phase IIIb, multicentre study to assess safety & immunogenicity of GSK Biologicals’ combined DTPa/Hib (Infanrix/Hib) vaccine vs separate administration of DTPa (Infanrix) & Hib (Hiberix) vaccines in healthy infants 3,4,&5 months of age as compared with the separate administration of DTPa and Hib vaccines at different injection sites." },{ "PostingID": 154, "Title": "GSK-111535", "Description": "Immunogenicity and reactogenicity study of GlaxoSmithKline Biologicals' Infanrix™/Hib vaccine administered as a booster dose to 18-24 months old children" },{ "PostingID": 155, "Title": "GSK-110474", "Description": "Long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine challenge in 7-8 year old children, previously vaccinated in infancy with GlaxoSmithKline (GSK) Biologicals' HBV vaccine." },{ "PostingID": 196, "Title": "GSK-110215", "Description": "Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months" },{ "PostingID": 253, "Title": "GSK-107137", "Description": "Prophylactic antipyretic treatment in children receiving booster dose of pneumococcal vaccine GSK1024850A and DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) and assessment of impact of pneumococcal vaccination on nasopharyngeal carriage" },{ "PostingID": 254, "Title": "GSK-109509", "Description": "Booster vaccination course with the pneumococcal vaccine GSK 1024850A, DTPw-HBV/Hib and OPV or IPV in children who completed the primary vaccination course in study 107007" },{ "PostingID": 255, "Title": "GSK-109621", "Description": "Safety, reactogenicity and immunogenicity following booster dose of GSK Biologicals´ pneumococcal conjugate vaccine when co-administered with a booster dose of Infanrix-IPV/Hib in preterm born children at 16-18 months of age" },{ "PostingID": 257, "Title": "GSK-110031", "Description": "Phase II, observer-blind follow-up study to assess reacto-and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), when given as booster in primed children or as 2-dose catch-up in unprimed children." },{ "PostingID": 258, "Title": "GSK-110521", "Description": "Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A co-administered with Zilbrix™ Hib and Polio Sabin™" },{ "PostingID": 260, "Title": "GSK-111188", "Description": "Primary vaccination course in healthy children receiving the pneumococcal vaccine GSK 1024850A co-administered with Tritanrix™-HepB/Hib at 6, 10 and 14 weeks of age" },{ "PostingID": 262, "Title": "GSK-112801", "Description": "Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children" },{ "PostingID": 264, "Title": "GSK-113166", "Description": "Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Malian children" },{ "PostingID": 265, "Title": "GSK-113199", "Description": "Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian children" },{ "PostingID": 266, "Title": "GSK-113266", "Description": "Evaluation of immunological persistence following 3-dose priming with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine in study NCT00808444 and safety and immunogenicity following a booster dose of the same vaccine" },{ "PostingID": 268, "Title": "GSK-112679", "Description": "Immunogenicity and safety of GSK Biologicals’ IPV (Poliorix™) in infants" },{ "PostingID": 270, "Title": "GSK-106260", "Description": "A Phase IIIb, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family." },{ "PostingID": 271, "Title": "GSK-106481", "Description": "Phase IIIb, Double Blind, Randomised, Placebo-Controlled, Multi-Country/Centre, Study to Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Pre-Term Infants" },{ "PostingID": 272, "Title": "GSK-107625", "Description": "Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants" },{ "PostingID": 273, "Title": "GSK-109216", "Description": "Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants." },{ "PostingID": 274, "Title": "GSK-109861", "Description": "Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix" },{ "PostingID": 275, "Title": "GSK-111654", "Description": "Non-inferiority of a commercial lot of the pneumococcal vaccine GSK1024850A compared to a clinical lot." },{ "PostingID": 276, "Title": "GSK-112269", "Description": "Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV" },{ "PostingID": 277, "Title": "GSK-113518", "Description": "Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants" },{ "PostingID": 280, "Title": "GSK-111344", "Description": "Immunogenicity and reactogenicity of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine when given as a booster dose." },{ "PostingID": 306, "Title": "GSK-110217", "Description": "Immunogenicity & safety study in preterm & full-term infants of GSK Biologicals' Hib-MenC vaccine, Menitorix™ co-administered with Infanrix™ penta & Prevenar™ at 2, 4, 6 months & as a booster with Infanrix™ IPV & Prevenar™ at 16-18 months" },{ "PostingID": 333, "Title": "GSK-105910", "Description": "Compare immunogenicity & reactogenicity of 2 formulations of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects" },{ "PostingID": 334, "Title": "GSK-217744/077 (DTPa-HBV-IPV-077)", "Description": "A phase III, double-blind, randomized, multicenter primary vaccination study to bridge the DTPa-HBV-IPV vaccine manufactured according to the large scale manufacturing process with the DTPa-HBV-IPV vaccine manufactured by the small scale manufacturing process when administered intramuscularly to infants at 2, 4 and 6 months of age, co-administered with Merck's Hib conjugate vaccine (Liquid PedvaxHIB®) in a separate injection at 2 and 4 months of age" },{ "PostingID": 336, "Title": "GSK-217744/085 (DTPa-Hep B-IPV-085)", "Description": "A phase III, open labeled, randomized, multicenter, clinical study of the safety and immunogenicity of a primary series of GlaxoSmithKline Biologicals' (GSK Biologicals') DTaP-HepBIPV candidate vaccine coadministered with HibTITER® and Prevnar® to healthy infants at 2, 4, and 6 months of age as compared to the separate administration of Infanrix® + Engerix-B® + IPOL® + HibTITER + Prevnar and to GSK Biologicals' DTaP-HepB-IPV candidate vaccine coadministered with HibTITER" },{ "PostingID": 337, "Title": "GSK-217744/097 (DTPa-HBV-IPV-097)", "Description": "Study to assess immunogenicity and reactogenicity of three doses of GSK Bio’s combined Hib-MenC vaccine co-admind with GSK Bio’s DTPa-HBV-IPV vaccine and of two doses of Baxters meningococcal C conjugate vaccine co-admind with GSK Bio’s DTPa-HBV-IPV/Hib vaccine" },{ "PostingID": 339, "Title": "GSK-101518 (DTPa-HBV-IPV-103)", "Description": "A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix-hexa) given as a booster at 18-24 months of age to children who have received a three-dose primary immunisation course with the same vaccine in a previous study" },{ "PostingID": 340, "Title": "GSK-104005", "Description": "Phase IIIb, open, randomized, multicenter study to assess the immunogenicity & safety of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in Indian infants when given at 6-10-14 weeks of age or at 2-4-6 months of age" },{ "PostingID": 341, "Title": "GSK-105555", "Description": "A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)" },{ "PostingID": 342, "Title": "GSK-106786", "Description": "A study to evaluate the immunogenicity and safety of a new formulation of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine as compared to the currently licensed Infanrix hexa in healthy infants (2,3,4 M)" },{ "PostingID": 343, "Title": "GSK-217744/076 (DTPa-HBV-IPV-076)", "Description": "An open, multicenter, phase IV clinical trial to assess the immunogenicity and reactogenicity of three doses of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine in healthy infants at 2, 4 and 6 months of age, when co-administered with Wyeth-Lederle’s meningococcal group C conjugate vaccine." },{ "PostingID": 344, "Title": "GSK-217744/078 (DTPa-HBV-IPV-078)", "Description": "An open, multicentre, phase IV clinical trial to assess the immunogenicity and reactogenicity of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, when co-administered at 3-4-5 Mth of age with Wyeth-Lederle's seven-valent pneumococcal conjugate vaccine at a different injection site during the same visit" },{ "PostingID": 345, "Title": "GSK-217744/081 (DTPa-HBV-IPV-081)", "Description": "An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of a 4th dose of GSK Biologicals’ combined DTPa-HBV-IPV/Hib vaccine, co-administered with Wyeth's seven-valent Pneumococcal conjugate vaccine at a different injection site during the same visit in healthy children" },{ "PostingID": 346, "Title": "GSK-217744/083 (DTPa-HBV-IPV-083)", "Description": "Study to assess immunogenicity and reactogenicity of GSK Bio’s combined DTPa-HBV-IPV/Hib vaccine in pre-term infants in comparison with term infants, administered as a booster dose to children who previously were primed with 3 doses of GSK Biologicals combined DTPa-HBV-IPV/Hib vaccine" },{ "PostingID": 347, "Title": "GSK-217744/086 (DTPa-HBV-IPV-086)", "Description": "Single-blind, multicentre, phase IV clinical trial to assess and compare the immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™) and Aventis Pasteur’s DTPa-HBV-IPV-Hib vaccine (Hexavac™) given as a primary vaccination course at 2, 4 and 6 months of age." },{ "PostingID": 348, "Title": "GSK-217744/090 (DTPa-HBV-IPV-090)", "Description": "A phase IV, open, multicentre study to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix hexa() given as a primary vaccination course at 2, 4 and 6 months of age to pre-term infants." },{ "PostingID": 351, "Title": "GSK-213503/049 (DTPa-IPV-049)", "Description": "An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course" },{ "PostingID": 352, "Title": "GSK-213503/050 (DTPa-IPV-050)", "Description": "Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel" },{ "PostingID": 359, "Title": "GSK-101197 (DTPa -127)", "Description": "An open, multicentric, phase IV clinical trial to assess the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined diphtheria-tetanus-acellular pertussis vaccine (Infanrix™) administered to healthy infants at 2, 4 and 6 months of age." },{ "PostingID": 361, "Title": "GSK-104871", "Description": "A multicentric study to compare the immunogenicity, safety & reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs. co-administration of GSK's DTPa vaccine & Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children" },{ "PostingID": 362, "Title": "GSK-208355/124 (APV-124)", "Description": "An open, 3.5 year, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa vaccine or GSK Biologicals’ DTPa vaccine or Chiron Behring’s Td vaccine + either Pasteur Merieux’s Pa vaccine or GSK Biologicals’ pa vaccine, administered as a booster dose at age 4-6 years in study 208355/118 (APV-118)" },{ "PostingID": 365, "Title": "GSK-213503/045 (DTPa-IPV-045)", "Description": "Study to compare immunogenicity and reactogenicity of GSK Bio’s DTPa-IPV vaccine, with GSK Bio’s DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age" },{ "PostingID": 366, "Title": "GSK-213503/046 (DTaP-IPV-046)", "Description": "Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ DTaP-IPV vaccine, with GSK Biologicals’ DTaP and Aventis Pasteur MSD’s IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals’ MMR vaccine" },{ "PostingID": 367, "Title": "GSK-213503/047", "Description": "Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age." },{ "PostingID": 368, "Title": "GSK-213503/048", "Description": "Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine" },{ "PostingID": 436, "Title": "GSK-106208", "Description": "To assess reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) at 2, 4 and 6 months of age." },{ "PostingID": 437, "Title": "GSK-101695", "Description": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs" },{ "PostingID": 438, "Title": "GSK-101696", "Description": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs" },{ "PostingID": 439, "Title": "GSK-101697", "Description": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs" },{ "PostingID": 440, "Title": "GSK-101698", "Description": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs" },{ "PostingID": 443, "Title": "GSK-103860/280", "Description": "Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs" },{ "PostingID": 448, "Title": "GSK-106744", "Description": "Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 7 to 9 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine" },{ "PostingID": 449, "Title": "GSK-106745", "Description": "Multicentre study to assess persistence of antibodies against hepatitis B & immune response to a hepatitis B challenge dose in healthy children 4 to 6 yrs old previously vaccinated with 4 doses of GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine" },{ "PostingID": 450, "Title": "GSK-106789", "Description": "Assess long-term persistence of hepatitis B antibodies & immune response to a hepatitis B vaccine (Engerix-B Kinder) challenge in children aged 4-5 yrs (previously primed & boosted in the 1st 2 yrs of life with DTPa-HBV-IPV/Hib vaccine)" },{ "PostingID": 454, "Title": "GSK-217744/069", "Description": "Immunogenicity and safety of GSK Biological’s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers" },{ "PostingID": 455, "Title": "GSK-217744/075 (DTPa-HBV-IPV-075)", "Description": "Phase III, open, randomised immunogenicity and reactogenicity study to assess the interchangeability between GSK Bios' DTPa-HBV-IPV/Hib and DTPa-IPV/Hib + HBV at 3rd dose of primary vac. course in children who received HBV vac. at birth and one month of age and DTPa-IPV/Hib vac at 3-4 Mth of age" },{ "PostingID": 464, "Title": "GSK-105539", "Description": "An open, randomized, phase IIIa study to evaluate the safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine, when administered intramuscularly according to a 2-4-11 months vaccination schedule" },{ "PostingID": 465, "Title": "GSK-105554", "Description": "Phase IIIa randomized, controlled study to assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine, when administered as a 3-dose primary immunization course before 6 months of age" },{ "PostingID": 466, "Title": "GSK-106623", "Description": "Multicentre immune memory study in healthy children following a 3 dose primary vaccination with Prevenar or GSK Biologicals' pneumococcal conjugate vaccine via the administration of a single booster dose of Pneumovax 23" },{ "PostingID": 467, "Title": "GSK-107058", "Description": "Evaluate immunogenicity, safety & reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine given as catch-up immunization in children older than 7 mo of age or as 3-dose primary immunization in children before 6 mo of age" },{ "PostingID": 468, "Title": "GSK-107706", "Description": "To assess safety, reactogenicity & immunogenicity of a booster dose of pneumococcal conjugate vaccine, co-admin with GSK Biologicals’ MMRV vaccine in children (2nd yr of life) primed with the pneumococcal conjugate vaccine in study 105553." },{ "PostingID": 471, "Title": "GSK-111736", "Description": "Vaccination course in children primed and boosted with pneumococcal vaccine GSK 1024850A and in age-matched unprimed children" },{ "PostingID": 472, "Title": "GSK-112807", "Description": "Vaccination with the pneumococcal vaccine GSK 1024850A or Prevenar™ at approximately 4 years of age in children primed with 3 doses of GSK 1024850A vaccine or Prevenar™ and boosted with 23-valent pneumococcal plain polysaccharide vaccine" },{ "PostingID": 509, "Title": "GSK-107017", "Description": "Multicentre study to assess the effect of prophylactic antipyretic treatment on the rate of febrile reactions following concomitant administration of GSK Biologicals’ 10-valent pneumococcal conjugate, Infanrix hexa and Rotarix vaccines" },{ "PostingID": 1283, "Title": "GSK-101555", "Description": "A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV" },{ "PostingID": 1284, "Title": "GSK-444563/013", "Description": "A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa" },{ "PostingID": 1285, "Title": "GSK-444563/022", "Description": "A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine" },{ "PostingID": 1293, "Title": "GSK-444563/033", "Description": "Study to assess the clinical consistency of three production lots of GSK Biologicals’ HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age" },{ "PostingID": 1294, "Title": "GSK-102247", "Description": "A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines" },{ "PostingID": 1295, "Title": "GSK-109810", "Description": "To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247)." },{ "PostingID": 1296, "Title": "GSK-102248", "Description": "Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants" },{ "PostingID": 1297, "Title": "GSK-111274", "Description": "Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants" },{ "PostingID": 1298, "Title": "GSK-103477", "Description": "Study to assess the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus" },{ "PostingID": 1299, "Title": "GSK-103478", "Description": "Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus" },{ "PostingID": 1300, "Title": "GSK-103992", "Description": "Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh" },{ "PostingID": 1301, "Title": "GSK-104480", "Description": "Compare the immunogenicity, reactogenicity & safety of 2 different formulations of GSK Biologicals’ live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV" },{ "PostingID": 1302, "Title": "GSK-105722", "Description": "A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam" },{ "PostingID": 1303, "Title": "GSK-107077", "Description": "A study to assess the immunogenicity, reactogenicity and safety of 2 different formulations of GSK Biologicals' live attenuated HRV vaccine, given as a two-dose primary vaccination, in healthy infants previously uninfected with HRV" },{ "PostingID": 1305, "Title": "GSK-107876", "Description": "Study to evaluate clinical consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate liquid formulation compared to lyophilised formulation of the HRV vaccine administered as a two-dose primary vaccination." },{ "PostingID": 1418, "Title": "GSK-103860/277", "Description": "Phase III study of immunogenicity and safety of 3 doses of GSK Biologicals' thimerosal-free hepatitis B vaccine compared to the US-licensed GSK Biologicals' preservative-free hepatitis B vaccine when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life" },{ "PostingID": 1423, "Title": "GSK-263855/035", "Description": "Phase IIIb study to evaluate immunogenicity, antibody persistency and reactogenicity of DTPa - INFANRIX and dTpa - BOOSTRIX vaccines administered to healthy children previously primed with 3 doses of DTPa vaccine compared to placebo (HAVRIX®JUNIOR)" },{ "PostingID": 1426, "Title": "GSK-711866/006 (dTpa-IPV-006)", "Description": "A phase III, open study to evaluate the immunogenicity, safety and reactogenicity of GSK Bios’ dTpa-IPV vaccine when administered as a booster vaccination to healthy children (6-8 Y) and previously vaccinated with 4 doses of DTPw and at least 3 doses of OPV/ IPV vaccines" },{ "PostingID": 1546, "Title": "GSK-113808", "Description": "Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Liquid Human Rotavirus (HRV) Vaccine (444563), in healthy infants" },{ "PostingID": 1691, "Title": "GSK-114260", "Description": "Immunogenicity and safety of GlaxoSmithKline Biologicals’ DTPa-IPV/Hib (Infanrix™-IPV+Hib) vaccine in healthy Korean infants" },{ "PostingID": 1747, "Title": "GSK-208108/091", "Description": "A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects" },{ "PostingID": 1748, "Title": "GSK-208108/092", "Description": "A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects" },{ "PostingID": 1749, "Title": "GSK-100381", "Description": "Study to assess safety, reactogenicity and immunogenicity of a booster dose of an investigational vaccination regimen and GSK Biologicals Hib-MenC vaccine (co-admind with Infanrix penta) compared to a booster dose of Menjugate (co-admind with Infanrix hexa)" },{ "PostingID": 1750, "Title": "GSK-792014/001", "Description": "A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule." },{ "PostingID": 1751, "Title": "GSK-792014/002", "Description": "A phase II, open, randomized, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of an investigational vaccination regimen versus ActHIB® and Menjugate® given concomitantly with Infanrix® penta and Prevenar® in infants" },{ "PostingID": 1752, "Title": "GSK-792014/003", "Description": "A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity, reactogenicity and safety of three different formulations of GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups C and Y- conjugate vaccine and one formulation of GSK Biologicals’ Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine each given concomitantly with InfanrixTM penta, versus MeningitecTM, given concomitantly with InfanrixTM hexa in infants according to a 2-3-4 month schedule" },{ "PostingID": 1753, "Title": "GSK-101858", "Description": "Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years" },{ "PostingID": 1754, "Title": "GSK-102015", "Description": "Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years" },{ "PostingID": 1759, "Title": "GSK-105987", "Description": "A single-blind, randomized, controlled, multinational study for the evaluation of safety of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen compared to monovalent Haemophilus influenzae type b (Hib) control vaccine in healthy infants at 2, 4, 6, and 12 to 15 months of age." },{ "PostingID": 1760, "Title": "GSK-107824", "Description": "A study to evaluate the long-term antibody persistence at 1, 3 & 5 years after the administration of a fourth dose of Hib-MenCY-TT Vaccine compared to ActHIB in subjects boosted in a previous study." },{ "PostingID": 1761, "Title": "GSK-102547", "Description": "Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec" },{ "PostingID": 1763, "Title": "GSK-103974", "Description": "Demonstrate non-inferiority of Men-C immune response of Hib-MenC with Infanrix™-IPV versus a licensed Men-C vaccine with Pediacel™ when given at 2, 3, 4 months and the immunogenicity of Hib-MenC when given as a booster dose at 12-15 months" },{ "PostingID": 1764, "Title": "GSK-104056", "Description": "Study to demonstrate the non-inferiority of the meningococcal serogroup C immune response of GlaxoSmithKline Biologicals’ Hib-MenC vaccine co-administered with Infanrix™-IPV versus a licensed meningococcal serogroup C vaccine co-administered with Pediacel™ vaccine" },{ "PostingID": 1766, "Title": "GSK-106390", "Description": "Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC given with Infanrix™ penta versus NeisVac-C™ given with Infanrix™ hexa at 3, 5 months of age and persistence prior to a Hib-MenC booster at 11 months and immunogenicity of the booster" },{ "PostingID": 1767, "Title": "GSK-106445", "Description": "Study to demonstrate non-inferiority of GSK Biologicals’ Hib-MenC with Priorix™, versus MenC-CRM197 vaccine with Hiberix™ & Priorix™ in toddlers primed with Hib but not MenC & to evaluate persistence up to 5 years after vaccination." },{ "PostingID": 1768, "Title": "GSK-106672", "Description": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097" },{ "PostingID": 1769, "Title": "GSK-109664", "Description": "Assessment of long-term antibody persistence after a booster dose of GSK Biologicals’ Hib & meningococcal C vaccine (Menitorix™) 811936 given at 12-15 months of age to subjects primed with 3 doses of Menitorix™ at 2, 3, 4 months of age" },{ "PostingID": 1771, "Title": "GSK-100566", "Description": "Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose" },{ "PostingID": 1772, "Title": "GSK-100567", "Description": "Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose" },{ "PostingID": 1773, "Title": "GSK-100568", "Description": "Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose" },{ "PostingID": 1774, "Title": "GSK-100569", "Description": "Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose" },{ "PostingID": 1775, "Title": "GSK-100570", "Description": "Evaluate Persistence of Immune Response of GSK Biologicals’ TWINRIX™ Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX™ JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 years at Time of First Vaccine Dose" },{ "PostingID": 2153, "Title": "GSK-103812", "Description": "Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)" },{ "PostingID": 2154, "Title": "GSK-104171", "Description": "Assess reactogenicity & safety of a booster of either Tritanrix™-HepB/Hib-MenAC or Tritanrix™-HepB/Hiberix™ given (single-blind) at 15-18 (Philippines)/15-24 mths (Thailand) & a dose of Mencevax™ ACWY at 24-30 mths (open label)" },{ "PostingID": 2156, "Title": "GSK-104727", "Description": "Assess immunogenicity, safety & reactogenicity of a 4th dose of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC at 15-24 m & of a dose of Mencevax™ ACWY at 24-30 m in subjects primed with 3 doses of Tritanrix™-HepB/Hib-MenAC" },{ "PostingID": 2157, "Title": "GSK-104733", "Description": "Demonstrate lot-to-lot consistency of final production method of GSK Biologicals' Hib-MenAC vaccine mixed extemporaneously with Tritanrix™-HepB & demonstrate its non-inferiority vs Tritanrix™-HepB/Hiberix™ in healthy infants at 2, 4 and 6 months" },{ "PostingID": 2158, "Title": "GSK-104065", "Description": "Immune memory of GSK's DTPw-HBV/Hib vaccine by giving Plain PRP polysaccharide at 10 mths. Immuno & reacto of a booster dose of DTPw-HBV/Hib or DTPw-HBV or DTPw-HBV+Hib at 15-18 mths in infants previously primed with DTPw-HBV/Hib" },{ "PostingID": 2159, "Title": "GSK-104489", "Description": "Study to assess immunogenicity and safety of GlaxoSmithKline Biologicals' Kft’s DTPw-HBV/Hib vs DTPwCSL-HBV/Hib Kft and vs concomitant administration of CSL’s Triple Antigen and GlaxoSmithKline Biologicals’ Hiberix, to infants at 2, 4, 6 months of age, after a birth dose of hepatitis B" },{ "PostingID": 2160, "Title": "GSK-106602", "Description": "Immunogenicity, Reactogenicity & Safety of a Booster Dose of GSK Biologicals’ DTPw-HBV/Hib Kft Vaccine Vs GSK Biologicals’ DTPw-HBV/Hib Vaccine, in Infants Who Received a 3-Dose Primary Vaccination Course With the Same Vaccines." },{ "PostingID": 2161, "Title": "GSK-103388", "Description": "Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life" },{ "PostingID": 2162, "Title": "GSK-104020", "Description": "Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life" },{ "PostingID": 2163, "Title": "GSK-104389", "Description": "Blinded, randomised, controlled study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ combined measles-mumps-rubella-varicella candidate vaccine given to healthy children in their second year of life" },{ "PostingID": 2164, "Title": "GSK-105908", "Description": "Comparative study evaluating the immunogenicity and safety of MeMuRu-OKA vaccine and measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with measles-mumps-rubella vaccine" },{ "PostingID": 2165, "Title": "GSK-105909", "Description": "Comparative study evaluating the immunogenicity & safety of MeMuRu-OKA vaccine & measles-mumps-rubella vaccine (Priorix™) co-administered with varicella vaccine (Varilrix™) in children primed with both measles-mumps-rubella & varicella vaccines" },{ "PostingID": 2171, "Title": "GSK-106673", "Description": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097" },{ "PostingID": 2172, "Title": "GSK-106675", "Description": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097" },{ "PostingID": 2173, "Title": "GSK-106679", "Description": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097" },{ "PostingID": 2174, "Title": "GSK-106680", "Description": "Phase III, open, multicenter Study to Assess the Long-Term Persistence of a Booster Dose of GSK Biologicals' Hib-MenC compared to a Booster Dose of Infanrix™ Hexa When Given to 14 month-old Subjects Primed in study DTPa-HBV-IPV-097 & Boosted in study Hib-MenC-TT-010 BST: DTPa-HBV-IPV-097" },{ "PostingID": 2179, "Title": "GSK-100386", "Description": "Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose" },{ "PostingID": 2180, "Title": "GSK-100387", "Description": "Evaluate the persistence of immune response of GSK Biologicals’ TWINRIX™ ADULT, administered according to 0,6 month schedule and 0,12 month schedule, in volunteers aged 12-15 years inclusive at the time of first vaccine dose" },{ "PostingID": 2194, "Title": "GSK-100448", "Description": "Long-Term Follow Up Study at Years 16-20, to Evaluate the Persistence of Immune Response of GlaxoSmithKline Biologicals' Hepatitis B Vaccine in Newborns of HBeAg+ and HBsAg+ Mothers" },{ "PostingID": 2205, "Title": "GSK-104730", "Description": "A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727." },{ "PostingID": 2206, "Title": "GSK-104756", "Description": "Booster Vaccination Study to Assess Safety & Reactogenicity of a Dose of DTPw-HBV/Hib Vaccine and to Assess the Immunogenicity, Safety & Reactogenicity of a Dose of Mencevax™ ACW in Subjects Primed in Study 759346/007" },{ "PostingID": 2207, "Title": "GSK-105239", "Description": "Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study" },{ "PostingID": 2208, "Title": "GSK-105245", "Description": "Booster Vaccination Study to Assess Immunogenicity & Safety of a Dose of GSK Biologicals' Mencevax™ ACWY & 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study" },{ "PostingID": 2209, "Title": "GSK-105553", "Description": "Assess lot-to-lot consistency of 3 lots (double blind design) of GlaxoSmithKline Biologicals' 10-valent pneumococcal vaccine and evaluate non-inferiority to Prevenar™ (single blind design) when administered as 3-dose primary immunization course before 6 months of age" },{ "PostingID": 2210, "Title": "GSK-107005", "Description": "To assess safety, reactogenicity and immunogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine, when co-administered with DTPa-combined vaccines and MenC or Hib-MenC vaccines during the first 6 months of age." },{ "PostingID": 2211, "Title": "GSK-107007", "Description": "To assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine compared to Prevenar™, co-administered with DTPw-HBV/Hib & OPV or IPV vaccines as a 3-dose primary immunization course during the first 6 months of age" },{ "PostingID": 2212, "Title": "GSK-107046", "Description": "To assess the safety, reactogenicity & immunogenicity of a 4th dose of GSK Biologicals’ pneumococcal vaccine or Prevenar™ in children (12-18 months) previously vaccinated in the primary study 105553 with either pneumococcal vaccine or Prevenar™" },{ "PostingID": 2213, "Title": "GSK-111345", "Description": "Long-term follow-up study to assess antibody persistence in children previously vaccinated with four doses of pneumococcal conjugate vaccine in primary vaccination study (105553) and booster vaccination study (107046)" },{ "PostingID": 2214, "Title": "GSK-109705", "Description": "Study of two formulations of GSK Biologicals' varicella vaccine given as a 2-dose course in the second year of life" },{ "PostingID": 2753, "Title": "GSK-217744/099", "Description": "A phase II, randomized, partially blinded clinical trial to evaluate the immunogenicity and reactogenicity of an investigational vaccine regimen of GSK Biologicals as compared to GSK Biologicals’ DTPa-HBV-IPV/Hib vaccine (Infanrix™ hexa) and to the concomitant administration of GSK Biologicals’ DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines, when given as a primary vaccination to healthy infants at 2, 3 and 4 months of age" },{ "PostingID": 2754, "Title": "GSK-759346/002", "Description": "Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects" },{ "PostingID": 2755, "Title": "GSK-100480", "Description": "Study to show lot-to-lot consistency of Hib-MenAC mixed with Tritanrix™-HBV, its non-inferiority to Tritanrix™-HBV/Hiberix™ with or without Meningitec™, and MenA response in 2, 4, 6 month infants with hepatitis B birth dose" },{ "PostingID": 2756, "Title": "GSK-100791", "Description": "Study to assess immunogenicity and non-inferiority of investigational vaccination regimen as compared to Tritanrix-HepB/Hiberix and as compared to Meningitec when administered to healthy infants" },{ "PostingID": 2757, "Title": "GSK-101222", "Description": "Study to demonstrate the non-inferiority of GSK Biologicals' DTPw-HBV/Hib Kft. vaccine compared to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine and to separate administration of DTPw-HBV Kft. and Hiberix™ vaccines with respect to the immunogenicity of all antigens, when administered to healthy infants." },{ "PostingID": 2758, "Title": "GSK-101223", "Description": "Study to assess the lot-to-lot consistency of the production method of GSK Biologicals' DTPw-HBV/ Hib Kft. vaccine and to compare to GSK Biologicals' Tritanrix™-HepB/Hiberix™ vaccine, when administered as a primary vaccination course." },{ "PostingID": 2759, "Title": "GSK-208136/039", "Description": "Follow-up to evaluate the the immunogenicity & safety of GSK Biologicals’ MMRV vaccine given as a two-dose schedule in the second year of life, as compared to separate administration of GSK Biologicals’ Priorix® & Varilrix®." },{ "PostingID": 2760, "Title": "GSK-208136/040", "Description": "Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines" },{ "PostingID": 2761, "Title": "GSK-208136/041", "Description": "Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children, as compared to separate administration of GSK Biologicals' Priorix® and Varilrix® vaccines" },{ "PostingID": 2762, "Title": "GSK-108760", "Description": "Immunogenicity & safety study of GSK Biologicals’ 208136 vaccine formulated with new measles and rubella working seeds" },{ "PostingID": 2763, "Title": "GSK-208136/038", "Description": "Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines" },{ "PostingID": 2768, "Title": "GSK-113615", "Description": "Feasibility study of GlaxoSmithKline Biologicals’ GSK2202083A vaccine in healthy infants at 2, 4 and 12 months of age" },{ "PostingID": 2778, "Title": "GSK-759346/009", "Description": "Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological’s Hiberix vaccine, extemporaneously mixed with GSK Biological’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age" },{ "PostingID": 2779, "Title": "GSK-112830", "Description": "Persistence of antibodies after full vaccination course with GSK Biologicals’ Menitorix or MenC conjugate vaccine, co-administered with DTPa or DTPa/Hib containing vaccine and pneumococcal conjugate vaccine, in children up to 6 years of age" },{ "PostingID": 2790, "Title": "GSK-102144", "Description": "Study to assess immunogenicity and reactogenicity of a booster dose of GSK Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to concomitant administration of CSL’s DTPw vaccine and GSK Biologicals' hepatitis B vaccine at separate injection sites and to GSK Biologicals' DTPw-HB vaccine" },{ "PostingID": 2791, "Title": "GSK-196131/001", "Description": "A phase III, partially double blind, randomized, multicentric study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals Kft’s combined DTPwCSL-HB vaccine as compared to Commonwealth Serum Laboratory’s (CSL’s) DTPwCSL (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B) administered concomitantly at separate injection sites and to GSK Biologicals’ DTPw-HB vaccine (Tritanrix™-HepB) when administered to healthy infants at 3, 4 and 5 months of age" },{ "PostingID": 2792, "Title": "GSK-104021", "Description": "A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine." },{ "PostingID": 2810, "Title": "GSK-111346", "Description": "Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age" },{ "PostingID": 2811, "Title": "GSK-111347", "Description": "Assessment of long-term antibody persistence and immunological memory in children previously vaccinated with four pneumococcal conjugate vaccine doses and assessment of pneumococcal catch-up vaccination with GSK1024850A at 5 years of age." },{ "PostingID": 2812, "Title": "GSK-112640", "Description": "Immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ pneumococcal vaccine GSK1024850A following primary and booster vaccination of healthy Japanese children" },{ "PostingID": 2813, "Title": "GSK-112909", "Description": "Booster vaccination with pneumococcal vaccine GSK1024850A in primed children and catch-up vaccination in unprimed children" },{ "PostingID": 2830, "Title": "GSK-100388", "Description": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine" },{ "PostingID": 3223, "Title": "GSK-217744/049 (DTPa-HBV-IPV-049)", "Description": "Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months" },{ "PostingID": 3224, "Title": "GSK-217744/061 (DTPa-HBV-IPV-061)", "Description": "Phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SB Bios' DTPa-HBV-IPV vaccine compared with Infanrix when both vaccines are co-administered with OmniHIB between 15 and 18 months of age after primary immunization at the age of 2, 4 and 6" },{ "PostingID": 3225, "Title": "GSK-347414/016", "Description": "A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine" },{ "PostingID": 3226, "Title": "GSK-347414/028", "Description": "A randomized, controlled, open, phase-II clinical study to evaluate the safety and immunogenicity of an experimental formulation extemporaneously mixed with SmithKline Beecham Biologicals' Haemophilus influenzae type b (Hib) vaccine, administered as a booster dose with DTPa-HBV-IPV to healthy children 12 to 18 months old" },{ "PostingID": 3227, "Title": "GSK-217744/070 (DTPa-HBV-IPV-070)", "Description": "An open clinical study to assess the immunogenicity and safety of GSK Bio’s DTPa-HBV-IPV vaccine mixed in one syringe with Hib vaccine, as a primary vaccination course to pre-term infants(<37 weeks) at 2, 4 and 6 months of age in comparison with infants born after normal gestation period" },{ "PostingID": 3228, "Title": "GSK-217744/060", "Description": "Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV)" },{ "PostingID": 3230, "Title": "GSK-217744/066 (DTPa-HBV-IPV-066)", "Description": "Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals’ HAV vaccine (Havrix(), in children in their second ..." },{ "PostingID": 3233, "Title": "GSK-217744/095 (DTPa-HBV-IPV-095)", "Description": "Study to assess immunogenicity and reactogenicity of GSK Bio’s DTPa-HBV-IPV/Hib vaccine when given as a booster dose to children previously primed at 2-4-6 months of age either with Aventis Pasteurs DTPa-HBV-IPV-Hib vaccine or GSK Bio’s DTPa-HBV-IPV/Hib vaccine in study DTPa-HBV-IPV-086" },{ "PostingID": 3234, "Title": "GSK-347414/020", "Description": "A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age" },{ "PostingID": 3235, "Title": "GSK-347414/026", "Description": "A Phase III, randomized single-blind clinical trial to assess the immune memory induced by an investigational vaccination regimen in comparison with Prevnar and the immune response to a fourth dose of the pneumococcal vaccine and the investigational vaccination regimen, when admininistered to healthy children (12-15 Months)" },{ "PostingID": 3236, "Title": "GSK-759348/001", "Description": "A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life" },{ "PostingID": 3237, "Title": "GSK-759348/003", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age." },{ "PostingID": 3239, "Title": "GSK-347414/023", "Description": "A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age." },{ "PostingID": 3241, "Title": "GSK-347414/017", "Description": "A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age" },{ "PostingID": 3242, "Title": "GSK-763674/002", "Description": "A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age." },{ "PostingID": 3243, "Title": "GSK-100478", "Description": "Study to show non-inferiority of Tritanrix™-HepB/Hib-MenAC (+/- hepatitis B vaccine at birth) versus Tritanrix™-HepB/Hiberix™ without hepatitis B vacc. at birth for antibody response to all vaccine antigens given in healthy infants" },{ "PostingID": 3245, "Title": "GSK-402764/004", "Description": "A phase III, open, randomized study to evaluate the immunogenicity and reactogenicity of investigational vaccination regimens" },{ "PostingID": 3246, "Title": "GSK-759346/001", "Description": "A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccinationregimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age." },{ "PostingID": 3247, "Title": "GSK-759346/007", "Description": "Demonstrate non-inferiority of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine" },{ "PostingID": 3248, "Title": "GSK-763674/001", "Description": "A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age." },{ "PostingID": 3249, "Title": "GSK-213501/018 (DTPw-HBV-Hib-018)", "Description": "Study to evaluate immunogenicity, safety and reactogenicity of two different immunization regimens against hepatitis B, diphtheria, tetanus, pertussis and Haemophilus influenzae type b (Hib)diseases in healthy infants primed with a birth dose of GSK Biologicals hepatitis B" },{ "PostingID": 3250, "Title": "GSK-213501/019 (DTPw-HBV-Hib-019)", "Description": "Study to assess immunogenicity and reactogenicity of GSK Bio’s quadrivalent diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus influenzae type b conjugate vaccines when mixed extemporaneously and given in a single injection to healthy infants" },{ "PostingID": 3257, "Title": "GSK-711866/001 (dTpa-IPV-001)", "Description": "A study to assess the lot-to-lot consistency of GSK Biologicals dTpa-IPV vaccine administered to healthy children 4 to 8 years of age, previously vaccinated with four doses of DTPa or DTPa-based combination vaccines and at least 3 doses of OPV or IPV" },{ "PostingID": 3260, "Title": "GSK-208355/123 (APV-123)", "Description": "A phase 3, open, multicenter study of the safety and immunogenicity of a booster dose of SB Bios’ Diphtheria and Tetanus toxoids and acellular Pertussis vaccine and Pasteur Mérieux’s Haemophilus influenzae type b conjugate vaccine when admin intramuscularly as separate injections(12-18 mths of age)" },{ "PostingID": 3285, "Title": "GSK-208108/087 (Hib-087)", "Description": "Phase 2 open randomized primary vaccination study to assess the immunogenicity and reactogenicity of GSK Biologicals' Haemophilus influenzae type b conjugate vaccine administered with commercially available DTPw vaccine as compared to GSK Biologicals' Hib administered mixed with GSK Biologicals' DTPw vaccine in healthy infants" },{ "PostingID": 3286, "Title": "GSK-347414/029", "Description": "Multinational, randomised, controlled, open, phase 2 clinical study to evaluate the safety and immunogenicity of GSK Biologicals’ investigational vaccination regimen administered as a booster dose to healthy children, previously vaccinated in infancy with the investigational vaccination regimen in a primary study 347414/017" },{ "PostingID": 3287, "Title": "GSK-347414/036", "Description": "A phase-3, open, controlled study to assess the safety and immunogenicity of four different formulations of GSK Biologicals’ investigational vaccination regimen when administered as a booster to healthy infants, 12 to 16 months old, previously vaccinated in infancy in a primary study 347414/023" },{ "PostingID": 3288, "Title": "GSK-371594/006", "Description": "A phase II, open, randomized study to assess the immune memory induced by a primary vaccination course of an investigational vaccination regimen and the immunogenicity and reactogenicity of a fourth dose of an investigational vaccination regimen, to healthy toddlers primed in study 371594/004." },{ "PostingID": 3293, "Title": "GSK-208127/122 (Ext-HAB-039 Month 90)", "Description": "An open study to evaluate the immunogenicity and reactogenicity of GlaxoSmithKline Biologicals’ combined hepatitis A / hepatitis B vaccine (schedule 0, 1, 6 months) in healthy children aged 1 to 6 years." },{ "PostingID": 3305, "Title": "GSK-103860/271 (Ext-HBV-064 Y14-Y15)", "Description": "Immunogenicity and protective efficacy of GlaxoSmithKline (GSK) recombinant-DNA hepatitis B vaccine (10 (g) in newborns of HBeAg+ and HBsAg+ mothers in comparison with a historical control group." },{ "PostingID": 3306, "Title": "GSK-208139/054 (DTPw-HBV-028 Ext. Y7)", "Description": "Study in infants vaccinated with Engerix-B to evaluate immunogenicity and reactogenicity of following GSK Bio’s vaccines: combined DTP-HB vaccine(10g HBsAg)combined DTP-HB vaccine(5g HBsAg) simultaneous administration of Engerix-B vaccine in right thigh and whole-cell DTP vaccine in left thigh" },{ "PostingID": 3307, "Title": "GSK-347414/008", "Description": "Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age" },{ "PostingID": 3308, "Title": "GSK-444563/007 (rota-007)", "Description": "Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age" },{ "PostingID": 3324, "Title": "GSK-104420", "Description": "A phase II study to evaluate the persistence of measles, mumps and rubella antibodies two years after the single dose primary vaccination in study 209762/151." },{ "PostingID": 3325, "Title": "GSK-209762/136 (MeMuRu-136)", "Description": "A phase III, blinded, randomized, multicenter U.S. study evaluating the clinical consistency of three production lots of SmithKline Beecham Biologicals' MMR vaccine (PRIORIX) and comparability of PRIORIX with Merck's M-M-R IIvaccine, administered to healthy children 12 to 18 months of age" },{ "PostingID": 3326, "Title": "GSK-209762/147 (MeMuRu-147)", "Description": "Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore." },{ "PostingID": 3327, "Title": "GSK-209762/148", "Description": "Phase II, double blind, randomized sequential study to compare immunogenicity and reactogenicity of the current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine containing human serum albumin with the modified formulations which do not contain HSA" },{ "PostingID": 3329, "Title": "GSK-209762/150", "Description": "Double blind, randomized sequential study to compare immunogenicity and reactogenicity of current formulations of GSK Bios’ measles-mumps-rubella vaccine and GSK Bios’ varicella vaccine to investigational vaccination regimens" },{ "PostingID": 3330, "Title": "GSK-209762/151", "Description": "Phase II study to evaluate immunogenicity, reactogenicity and safety of GSK Bios’ investigational vaccination regimen compared to the currently licensed GSK Bios’ Priorix™ and Merck and Co.’s M-M-R®II vaccines when administered as a primary vaccination to healthy children aged 12-24 months" },{ "PostingID": 3336, "Title": "GSK-711202/001", "Description": "Evaluate immunogenicity, reactogenicity, safety of GSK Biologicals’ MenC-TT vaccine (2 formulations) given with Infanrix hexa® + GSK Biologicals’ Hib MenC-TT vaccine (2 formulations) given with Infanrix penta® to infants in mths 3,4,5 of life" },{ "PostingID": 3337, "Title": "GSK-711202/008", "Description": "Evaluate the persistence and immune memory induced by a primary vaccination course with GSK Biologicals’ MenC-TT (1 formulation) & GSK Biologicals’ Hib-MenC-TT (2 formulations) or Meningitec™ in healthy toddlers aged 12-15 mths primed in study 711202/001" },{ "PostingID": 3338, "Title": "GSK-811936/001 (Hib-MenC-TT-001)", "Description": "Phase 2, open, randomized, controlled study to demonstrate the non-inferiority of the meningococcal serogroup C immune response and the superiority of the Hib immune response of GSK Biologicals’ Haemophilus influenzae type b-meningococcal C-TT conjugate vaccine administered with Infanrix™ penta versus Meningitec™ administered with Infanrix™" },{ "PostingID": 3346, "Title": "GSK-444563/003 (rota-003)", "Description": "A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus." },{ "PostingID": 3347, "Title": "GSK-444563/004", "Description": "A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants." },{ "PostingID": 3348, "Title": "GSK-444563/005 (rota-005)", "Description": "Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Bios’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus" },{ "PostingID": 3350, "Title": "GSK-444563/014 (Rota-014)", "Description": "Study of safety, reactogenicity and immunogenicity of two doses of GSK Bio’s oral live attenuated human rotavirus vaccine co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants in South Africa" },{ "PostingID": 3351, "Title": "GSK-444563/020", "Description": "Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age" },{ "PostingID": 3352, "Title": "GSK-444563/021", "Description": "Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals’ live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age" },{ "PostingID": 3389, "Title": "GSK-711866/005 (dTpa-IPV-005, one year follow-up of dTpa-IPV-001)", "Description": "Open, 1-year, phase III, immunogenicity follow-up of subjects who previously received GSK Biologicals’ dTpa-IPV vaccine or GSK Biologicals’ dTpa (BoostrixTM) and Pasteur Mérieux’s IPV vaccine (IPV Mérieux() administered separately, at 4 to 8 years of age in study 711866/001 (dTpa-IPV-001)" },{ "PostingID": 3640, "Title": "GSK-115375", "Description": "Antibody persistence in children previously vaccinated with three doses of Infanrix hexa™ or Infanrix-IPV/Hib™" },{ "PostingID": 3641, "Title": "GSK-104690", "Description": "Blinded, randomized study to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals’ measles-mumps-rubella-varicella candidate vaccine given to healthy children during the second year of life" },{ "PostingID": 3642, "Title": "GSK-208136/006 (MeMuRu-OKA-006)", "Description": "Study evaluating in healthy children safety and immunogenicity of GSK Bios' combined Measles-Mumps-Rubella-Varicella vaccine, compared to GSK Bios' Varicella and Measles-Mumps-Rubella vaccines admind as separate injections" },{ "PostingID": 3643, "Title": "GSK-208136/013 (MeMuRu-OKA-013)", "Description": "Study to assess immunogenicity and safety of one dose of GSK Bios’ live attenuated MMRV vaccine, co-admind with a booster dose of the GSK Bios’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b conjugate vaccine" },{ "PostingID": 3645, "Title": "GSK-208136/018 (MeMuRu-OKA-018)", "Description": "Study to evaluate immunogenicity and safety of GSK Bios’ MeMuRu-OKA vaccine compared to concomitant administrations of GSK Bios’ Priorix™ and Varilrix™ vaccines" },{ "PostingID": 3655, "Title": "GSK-100565", "Description": "An open study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals' commercially available combined hepatitis A / hepatitis B vaccine (TWINRIX ADULT) containing 720 ELISA units of hepatitis A antigen and 20 µg of hepatitis B surface antigen, administered following a two-dose (0, 6 months) schedule in healthy children between the ages of 1 and 11 years" },{ "PostingID": 3669, "Title": "GSK-111870", "Description": "A phase II, randomized, observer blind, controlled, multicenter study to assess immunogenicity and antibody persistence following vaccination with GSK's candidate combined measles, mumps, and rubella vaccine (MMR) versus M-M-R® II as a first dose, both administered subcutaneously at 12-15 months of age, concomitantly with hepatitis A vaccine (HAV), varicella vaccine (VV) and pneumococcal conjugate vaccine (PCV) but at separate sites." },{ "PostingID": 3670, "Title": "GSK-RTX114351", "Description": "Immunogenicity, reactogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy Taiwanese infants who received hepatitis B immunoglobulin after birth." },{ "PostingID": 3707, "Title": "GSK-208136/007 (MeMuRu-OKA-007)", "Description": "Study to assess consistency of 3 production lots of GSK Bios’ combined measles-mumps-rubella-varicella vaccine in terms of immunogenicity and safety, compared to administration of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine in healthy children in their second year of life" },{ "PostingID": 3709, "Title": "GSK-208136/016 (MeMuRu-OKA-016)", "Description": "Study to assess immunogenicity and safety of two lots of GSK Bios’ live attenuated measles-mumps-rubella-varicella vaccine, at two different titres, given as a single injection to healthy children with GSK Bios’ measles-mumps-rubella vaccine as control group" },{ "PostingID": 3710, "Title": "GSK-208136/022 (MeMuRu-OKA-022)", "Description": "Study to evaluate immunogenicity and safety of one dose of GSK Bios’ combined measles-mumps-rubella-varicella vaccine compared to concomitant administrations of GSK Bios’ measles-mumps-rubella vaccine and varicella vaccine" },{ "PostingID": 3726, "Title": "GSK-V72P13", "Description": "A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants" },{ "PostingID": 3727, "Title": "GSK-V72P13E1", "Description": "A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13" },{ "PostingID": 3728, "Title": "GSK-V72P12", "Description": "A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules." },{ "PostingID": 4236, "Title": "GSK-209762/146 (MMR-146)", "Description": "Open, multicentre study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals live attenuated Measles-Mumps-Rubella vaccine (Priorix) given to healthy children at the age of 12 to 15 months or 4- 6 years" },{ "PostingID": 4289, "Title": "GSK-103488", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of different formulations of GlaxoSmithKline Biologicals’ 11-valent pneumococcal conjugate vaccine, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age" },{ "PostingID": 4501, "Title": "GSK-113171", "Description": "Safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen in children aged 12-23 months at the time of first vaccination." },{ "PostingID": 4502, "Title": "GSK-114174", "Description": "Impact of GSK Biologicals’ 2189242A vaccine on nasopharyngeal carriage, safety and immunogenicity when co-administered with routine EPI vaccines in infants following safety assessment in children aged 2-4 years in The Gambia" },{ "PostingID": 4515, "Title": "GSK-112921", "Description": "Impact of immediate or delayed prophylactic antipyretic treatment on the immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals’ pneumococcal vaccine 1024850A and the co-administered DTPa-combined vaccines" },{ "PostingID": 4590, "Title": "GSK-104105", "Description": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine" },{ "PostingID": 4591, "Title": "GSK-104106", "Description": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine" },{ "PostingID": 4592, "Title": "GSK-103494", "Description": "Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine" },{ "PostingID": 4632, "Title": "GSK-111157", "Description": "Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India" },{ "PostingID": 4667, "Title": "GSK-114306", "Description": "Immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals’ IPV (PoliorixTM) in healthy Chinese toddlers" },{ "PostingID": 4670, "Title": "GSK-103792", "Description": "A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose" },{ "PostingID": 4797, "Title": "GSK-111634", "Description": "Primary and booster vaccination course in human immunodeficiency virus (HIV) infected infants, HIV exposed uninfected infants and unexposed uninfected infants receiving the pneumococcal vaccine GSK 1024850A." },{ "PostingID": 4969, "Title": "GSK-114056", "Description": "Immunogenicity, safety and reactogenicity of GSK Biologicals’ pneumococcal vaccine 1024850A when administered to children between 8 weeks and 2 years of age" },{ "PostingID": 5119, "Title": "GSK-205249", "Description": "A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Meningococcal B Recombinant Vaccine When Administered concomitantly with Routine Vaccines to Healthy Infants in Taiwan." },{ "PostingID": 5120, "Title": "GSK-115884", "Description": "Immunogenicity, safety and reactogenicity study of GSK Biologicals’ pneumococcal vaccine (Synflorix™) when administered to children who are at an increased risk of pneumococcal infection" },{ "PostingID": 14526, "Title": "GSK-111763", "Description": "Immunogenicity and safety of GSK Biologicals’ dTpa-IPV vaccine (Boostrix Polio) as a booster dose in 3 and 4-year-old children" },{ "PostingID": 14527, "Title": "GSK-759348/002", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life" },{ "PostingID": 14528, "Title": "GSK-759348/007", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age." },{ "PostingID": 14529, "Title": "GSK-101853", "Description": "A randomized, controlled, phase II study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization (2-3-4 month schedule) before 6 months of age." },{ "PostingID": 19555, "Title": "GSK-115649", "Description": "Immunogenicity and safety study of GSK Biologicals’ Priorix vaccine (209762) at an end of shelf-life potency compared to Merck & Co., Inc.’s measles-mumps-rubella (MMR) vaccine when both are given on a 2-dose schedule to healthy children in their 2nd year of life" },{ "PostingID": 19556, "Title": "GSK-115650", "Description": "Safety and immunogenicity study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine, in healthy children 12 to 15 months of age" },{ "PostingID": 19608, "Title": "GSK-115555", "Description": "Immunogenicity and safety study of GlaxoSmithKline Biological's live attenuated measles mumps rubella varicella vaccine (PriorixTetra™) when co-administered with conjugated Meningococcal C vaccine (Meningitec®, Nuron Biotechs’ Vaccine) in healthy children" },{ "PostingID": 19668, "Title": "GSK-205240", "Description": "A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal group B Vaccine When Administered Concomitantly with GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants" },{ "PostingID": 19770, "Title": "GSK-113994", "Description": "Safety, reactogenicity & immunogenicity of GSK Biologicals’ pneumococcal vaccine 2189242A when co-administered with DTPa-HBV-IPV/Hib vaccine in healthy infants" },{ "PostingID": 19836, "Title": "GSK-200147", "Description": "Safety and immunogenicity study of 2 formulations of GSK Biologicals’ varicella vaccines given as a 2-dose course in the second year of life." },{ "PostingID": 19838, "Title": "GSK-115158", "Description": "Immunogenicity and safety study of GSK Biologicals’ combined measles-mumps-rubella vaccine in subjects four to six years of age (209762)" },{ "PostingID": 19887, "Title": "GSK-115648", "Description": "Consistency study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) (Priorix) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine (M-M-R II), in healthy children 12 to 15 months of age" },{ "PostingID": 20051, "Title": "GSK-114843", "Description": "Safety and immunogenicity of a booster dose of new formulations of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib vaccine (GSK217744)" },{ "PostingID": 20276, "Title": "GSK-201330", "Description": "Immunogenicity and safety study of GSK Biologicals’ combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-virus and Haemophilus influenzae type b vaccine (Infanrix hexa™) (217744) in healthy infants born to mothers vaccinated with Boostrix™ during pregnancy or immediately post-delivery" },{ "PostingID": 20392, "Title": "GSK-115461 (Rota-081)", "Description": "Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks" },{ "PostingID": 20721, "Title": "GSK-201532", "Description": "Evaluation of immunogenicity, safety and reactogenicity of GSK Biologicals’ dTpa booster vaccine (263855) (Boostrix) administered as a booster dose in healthy Russian subjects" },{ "PostingID": 20769, "Title": "GSK-115992", "Description": "Two-dose primary vaccination with either GSK Biologicals' 10-valent pneumococcal vaccine (Synflorix™) or Pfizer’s Prevenar 13™ or both vaccines followed by a booster dose of Synflorix™" },{ "PostingID": 20770, "Title": "GSK-115373", "Description": "Safety and immunogenicity study of GSK Biologicals’ pneumococcal vaccine 2830930A when administered as a single dose in healthy toddlers aged 12-23 months" }]